[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
2. Zali A, Shahzadi S, Mohammad-Mohammadi A, Taherzadeh K, Parsa K: Cerebral lymphoma: clinical and radiological findings in 90 cases. Arch Iran Med; 2007 Apr;10(2):194-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral lymphoma: clinical and radiological findings in 90 cases.
  • BACKGROUND: Cerebral lymphoma is a rare non-Hodgkin's lymphoma, which involves the brain primarily or after systemic involvement.
  • METHODS: The data from all cases in whom the cerebral lymphomas were pathologically confirmed and were admitted to the Neurosurgery Department of Shohada Hospital for stereotactic biopsy during a 15-year period were analyzed retrospectively.
  • Systemic lymphoma was detected in nine patients and three patients had a history of immunosuppressive drug consumption.
  • [MeSH-major] Brain Neoplasms / radiography. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367223.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


3. Becherer A, Jaeger U, Szabo M, Kletter K: Prognostic value of FDG-PET in malignant lymphoma. Q J Nucl Med; 2003 Mar;47(1):14-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of FDG-PET in malignant lymphoma.
  • Lymphomas have represented an indication for nuclear medicine investigations for 30 years.
  • Gallium-67 scintigraphy has been shown to be a valuable complementary method in Hodgkin's disease and non-Hodgkin lymphoma for detecting viable residual lesions after chemotherapy and for diagnosis of a relapse.
  • Thallium-201 is of interest in differentiating cerebral lymphomas from infectious lesions in AIDS patients but less useful in extra-cerebral lymphomas.
  • PET with fluorine-18-FDG is more accurate than 67Ga in lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma / drug therapy. Lymphoma / radionuclide imaging
  • [MeSH-minor] Citrates. Gallium. Hodgkin Disease / radionuclide imaging. Hodgkin Disease / therapy. Indium Radioisotopes. Lymphoma, Non-Hodgkin / radionuclide imaging. Lymphoma, Non-Hodgkin / therapy. Neoplasm Staging / methods. Prognosis. Radiopharmaceuticals. Thallium. Tomography, Emission-Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. GALLIUM .
  • Hazardous Substances Data Bank. THALLOUS CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12714950.001).
  • [ISSN] 1125-0135
  • [Journal-full-title] The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
  • [ISO-abbreviation] Q J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Citrates; 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 27905-02-8 / gallium citrate; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium; CH46OC8YV4 / Gallium
  • [Number-of-references] 59
  •  go-up   go-down


Advertisement
4. Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, Benci A, Sparano JA: Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res; 2002;159:149-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study.
  • iCDE) is one of the most effective chemotherapeutic regimen for human immunodeficiency virus (HIV)-associated non-Hodgkin's lymphoma (NHL), with a complete remission rate of 46% and a median overall survival of 8.2 months (Sparano JA, Blood 1993; 81:2810).
  • Characteristics of 29 evaluable patients were: median age: 38 years (range 29-65 years); male sex 24/29; histology: DLCL 16 (55%), Burkitt 10 (35%), ALCL 2 (7%), unclassified 1 (3%); stage: I (35%), II (10%), III (10%), IV (45%); International Prognostic Index: 0, 1 (59%), 2 (24%), 3 (17%), 4, 5 (0); CD4 count: median 132/ mm3 (range 3-470/mm3).
  • Twenty-six of 29 patients received treatment as planned, while chemotherapy had to be discontinued in three patients (2 persistent thrombocytopenias, 1 cerebral hemorrhage).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Drug Therapy, Combination. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Rituximab. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11785839.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; ACE protocol 1
  •  go-up   go-down


5. Blay JY, Ongolo-Zogo P, Sebban C, Carrie C, Thiesse P, Biron P: Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer. Ann Oncol; 2000;11 Suppl 1:39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer.
  • BACKGROUND: Primary cerebral non-Hodgkin's lymphomas (NHL) in immunocompetent patients (PCL) are located exclusively in the central nervous system, the eye, or meninges.
  • The overall survival of primary cerebral lymphoma (PCL) patients in the published series, a median of 12-16 months and a five-year survival of 5%-20%, is poor.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707777.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 28
  •  go-up   go-down


6. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI: Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1569-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
  • The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL).
  • Of the 33 patients, 2 patients experienced disease progression and subsequently died of their disease, 2 patients experienced disease progression but were alive at last follow-up following additional therapy, and 2 patients died without experiencing disease progression: one due to a cerebral vascular accident at 9 months after therapy and a second patient due to small cell lung carcinoma at 55 months.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cause of Death. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Male. Middle Aged. Prednisone / administration & dosage. Remission Induction. Rituximab. Survival Analysis. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236611.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Okada S: [Recent advances in the treatment of AIDS-related malignant lymphoma]. Nihon Rinsho; 2010 Mar;68(3):491-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent advances in the treatment of AIDS-related malignant lymphoma].
  • The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • However, the number of HIV-associated non-Hodgkin's lymphoma patients has increased with the increase of HIV-1 infected patients in Japan.
  • Although the evidence currently supports an intensive and curative approach for the management of HIV-associated lymphoma, we must be vigilant about adverse effects and interaction of chemotherapeutic drugs, implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20229796.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 29
  •  go-up   go-down


8. Baeuerle M, Schmitt-Haendle M, Taubald A, Mueller S, Walter H, Pfeiffer C, Manger B, Harrer T: Severe HIV-1 encephalitis and development of cerebral non-Hodgkin lymphoma in a patient with persistent strong HIV-1 replication in the brain despite potent HAART -- case report and review of the literature. Eur J Med Res; 2005 Jul 29;10(7):309-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe HIV-1 encephalitis and development of cerebral non-Hodgkin lymphoma in a patient with persistent strong HIV-1 replication in the brain despite potent HAART -- case report and review of the literature.
  • Despite therapy with a four drug antiretroviral combination regimen including two protease-inhibitors (PI), plasma viral load could not be suppressed sufficiently with persistence of low level viremia of 3.08-3.40 log copies/ml, even after addition of two other antiretroviral drugs.
  • 17 months after start of HAART, the patient developed a cerebral Non-Hodgkin lymphoma, leading to his death despite radiation therapy.
  • Nevertheless, subgroups of patients are infected with neurotropic viral variants which could cause progressive neurological pathology as they can not be reached sufficiently by the available drugs.
  • These patients require the development of new drugs that achieve a better penetration into the brain.
  • [MeSH-major] AIDS Dementia Complex / complications. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / etiology. Lymphoma, AIDS-Related / etiology. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Brain / pathology. Brain / virology. Fatal Outcome. HIV-1 / drug effects. HIV-1 / physiology. Humans. Magnetic Resonance Imaging. Male. Virus Replication / drug effects. Virus Replication / physiology


9. Sparano JA: Clinical aspects and management of AIDS-related lymphoma. Eur J Cancer; 2001 Jul;37(10):1296-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical aspects and management of AIDS-related lymphoma.
  • The incidence of non-Hodgkin's lymphoma (NHL) is increased by approximately 100-fold in patients with advanced HIV infection.
  • Clinical presentations may include systemic lymphoma, primary central nervous system (CNS) lymphoma, and primary effusion lymphoma.
  • Systemic lymphoma is the most common presentation, is almost always of intermediate or high-grade histology and B-cell phenotype, and usually involves extranodal sites.
  • The disease is potentially curable with combination chemotherapy used for immunocompetent patients with lymphoma, although cure is achieved in only approximately 10-35% of patients.
  • Primary CNS lymphoma may be difficult to distinguish from cerebral infection.
  • Evidence suggests that highly active antiretroviral therapy (HAART) has resulted in a decreased incidence of lymphoma, and that patients with systemic lymphoma treated in the post-HAART era have a better prognosis.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / prevention & control. Anti-HIV Agents / therapeutic use. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / drug therapy. Clinical Trials, Phase III as Topic. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Hematopoiesis. Humans. Infusions, Intravenous

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11423261.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 85
  •  go-up   go-down


10. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M: Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis; 2009 Apr 15;48(8):1138-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretroviral therapy, and CD4+ cell count and HIV RNA load at initiation of combination antiretroviral therapy.
  • The greatest mortality hazard ratio was associated with non-Hodgkin's lymphoma (hazard ratio, 17.59; 95% confidence interval, 13.84-22.35) and progressive multifocal leukoencephalopathy (hazard ratio, 10.0; 95% confidence interval, 6.70-14.92).
  • Three groups of ADEs were identified on the basis of the ranked hazard ratios with bootstrapped confidence intervals: severe (non-Hodgkin's lymphoma and progressive multifocal leukoencephalopathy [hazard ratio, 7.26; 95% confidence interval, 5.55-9.48]), moderate (cryptococcosis, cerebral toxoplasmosis, AIDS dementia complex, disseminated Mycobacterium avium complex, and rare ADEs [hazard ratio, 2.35; 95% confidence interval, 1.76-3.13]), and mild (all other ADEs [hazard ratio, 1.47; 95% confidence interval, 1.08-2.00]).

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Mycobacterium avium Complex and Atypical Mycobacterial Infections in the Setting of HIV Infection .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Jul 13;360(9327):119-29 [12126821.001]
  • [Cites] JAMA. 2003 May 21;289(19):2554-9 [12759327.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] JAMA. 2004 Jul 14;292(2):180-9 [15249567.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] N Engl J Med. 1981 Dec 10;305(24):1425-31 [6272109.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):402-3 [2992336.001]
  • [Cites] JAMA. 1987 Sep 4;258(9):1143-5, 1149, 1153-4 [3041060.001]
  • [Cites] Ann Intern Med. 1991 Aug 1;115(3):184-9 [1676252.001]
  • [Cites] J Acquir Immune Defic Syndr. 1991;4(10):1059-71 [1890600.001]
  • [Cites] JAMA. 1992 Nov 18;268(19):2662-6 [1359163.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] BMJ. 1994 Apr 23;308(6936):1068-73 [7909698.001]
  • [Cites] Stat Med. 1994 Oct 15-30;13(19-20):2107-25 [7846414.001]
  • [Cites] AIDS. 1995 Jan;9(1):57-63 [7893442.001]
  • [Cites] Arch Intern Med. 1995 Jul 24;155(14):1537-42 [7605156.001]
  • [Cites] Int J Epidemiol. 1997 Apr;26(2):400-7 [9169177.001]
  • [Cites] AIDS. 1998 Jan 1;12(1):29-33 [9456252.001]
  • [Cites] Nat Med. 1998 Feb;4(2):208-14 [9461195.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):543-9 [9492772.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):121-30 [15561752.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):399-406 [15750393.001]
  • [Cites] Infection. 2005 Feb;33(1):43-5 [15750761.001]
  • [Cites] BMJ. 2005 Mar 12;330(7491):594-6 [15761002.001]
  • [Cites] J Infect Dis. 2005 Sep 15;192(6):992-1002 [16107951.001]
  • [Cites] Lancet. 2006 Mar 11;367(9513):817-24 [16530575.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2283-96 [17135583.001]
  • [Cites] AIDS. 2007 May 31;21(9):1185-97 [17502729.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1867-75 [17721094.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):111-8 [12048371.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):451-8 [11141245.001]
  • [Cites] J Infect Dis. 2002 Jan 15;185(2):178-87 [11807691.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):388-95 [11917244.001]
  • (PMID = 19275498.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA013566-08; United States / NIAAA NIH HHS / AA / U10 AA013566; United Kingdom / Medical Research Council / / G0700820; United States / NIAAA NIH HHS / AA / U10 AA013566-08
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS264818; NLM/ PMC3032444
  • [Investigator] Casabona J; Chêne G; Costagliola D; Dabis F; D'Arminio Monforte A; de Wolf F; Egger M; Fatkenheuer G; Gill J; Hogg R; Justice A; Kitahata M; Ledergerber B; Mocroft A; Phillips A; Reiss P; Saag M; Sabin C; Staszewski S; Weller I; May M; Harris R; Sterne J; Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Duvivier C; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong MA; Lang JM; Lascaux AS; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard JL; Pavie J; Pialoux G; Pilorgé F; Poizot-Martin I; Pradier C; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard JP; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Guiguet M; Kousignian I; Lanoy E; Lièvre L; Potard V; Selinger-Leneman H; Bouvet E; Crickx B; Ecobichon JL; Leport C; Picard-Dahan C; Yeni P; Tisne-Dessus D; Weiss L; Salmon D; Sicard D; Auperin I; Roudière L; Fior R; Delfraissy JF; Goujard C; Jung C; Lesprit P; Desplanque N; Meyohas MC; Picard O; Cadranel J; Mayaud C; Bricaire F; Herson S; Clauvel JP; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine JL; Trepo C; Ravaux I; Delmont JP; Moreau J; Gastaut JA; Retornaz F; Soubeyrand J; Allegre T; Blanc PA; Galinier A; Ruiz JM; Lepeu G; Granet-Brunello P; Esterni JP; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; May T; Rabaud C; Raffi F; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand MF; Yasdanpanah Y; Pradinaud R; Sobesky M; Contant M; Montroni M; Scalise G; Braschi MC; Riva A; Tirelli U; Martellotta F; Pastore G; Ladisa N; Suter F; Arici C; Chiodo F; Colangeli V; Fiorini C; Carosi G; Cristini G; Torti C; Minardi C; Bertelli D; Quirino T; Manconi PE; Piano P; Cosco L; Scerbo A; Vecchiet J; D'Alessandro M; Santoro D; Pusterla L; Carnevale G; Lorenzotti S; Viganò P; Mena M; Ghinelli F; Sighinolfi L; Leoncini F; Mazzotta F; Pozzi M; Lo Caputo S; Grisorio B; Ferrara S; Grima P; Grima PF; Pagano G; Cassola G; Alessandrini A; Piscopo R; Toti M; Trezzi M; Soscia F; Tacconi L; Orani A; Perini P; Scasso A; Vincenti A; Chiodera F; Castelli P; Scalzini A; Palvarini L; Moroni M; Lazzarin A; Rizzardini G; Caggese L; Cicconi P; Galli A; Merli S; Pastecchia C; Moioli MC; Esposito R; Mussini C; Abrescia N; Chirianni A; Izzo CM; Piazza M; De Marco M; Viglietti R; Manzillo E; Nappa S; Colomba A; Abbadessa V; Prestileo T; Mancuso S; Ferrari C; Pizzaferri P; Filice G; Minoli L; Bruno R; Novati S; Baldelli F; Camanni G; Petrelli E; Cioppi A; Alberici F; Ruggieri A; Menichetti F; Martinelli C; De Stefano C; La Gala A; Ballardini G; Rizzo E; Magnani G; Ursitti MA; Arlotti M; Ortolani P; Cauda R; Dianzani F; Ippolito G; Antinori A; Antonucci G; Ciardi M; Narciso P; Petrosillo N; Vullo V; De Luca A; Zaccarelli M; Acinapura R; De Longis P; Trotta MP; Noto P; Lichtner M; Capobianchi MR; Carletti F; Girardi E; Pezzotti P; Rezza G; Mura MS; Mannazzu M; Caramello P; Di Perri G; Orofino GC; Sciandra M; Grossi PA; Basilico C; Poggio A; Bottari G; Raise E; Ebo F; Pellizzer G; Buonfrate D; Resta F; Loso K; Cozzi Lepri A; Battegay M; Bernasconi E; Böni J; Bucher H; Bürgisser P; Cattacin S; Cavassini M; Dubs R; Elzi L; Erb P; Fischer M; Flepp M; Fontana A; Francioli P; Furrer H; Gorgievski M; Günthard H; Hirsch H; Hirschel B; Hösli I; Kahlert C; Kaiser L; Karrer U; Kind C; Klimkait T; Martinetti G; Martinez B; Müller N; Nadal D; Opravil M; Paccaud F; Pantaleo G; Rickenbach M; Rudin C; Schmid P; Schultze D; Schüpbach J; Speck R; Taffé P; Tarr P; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S; Gras LA; van Sighem AI; Smit C; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Branger J; Eeftinck Schattenkerk JK; Gisolf J; Godfried MH; Lange JM; Lettinga KD; van der Meer JT; Nellen FJ; van der Poll T; Ruys TA; Steingrover R; Vermeulen JN; Vrouenraets SM; van Vugt M; Wit FW; Kuijpers TW; Pajkrt D; Scherpbier HJ; van Eeden A; Brinkman K; van den Berk GE; Blok WL; Frissen PH; Roos JC; Schouten WE; Mulder JW; van Gorp EC; Wagenaar J; Veenstra J; Danner SA; Van Agtmael MA; Claessen FA; Perenboom RM; Rijkeboer A; van Vonderen MG; Richter C; van der Berg J; Vriesendorp R; Jeurissen FJ; Kauffmann RH; Pogány K; Bravenboer B; ten Napel CH; Kootstra GJ; Sprenger HG; van Assen S; van Leeuwen JT; Doedens R; Scholvinck EH; ten Kate RW; Soetekouw R; van Houte D; Polée MB; Kroon FP; van den Broek PJ; van Dissel JT; Schippers EF; Schreij G; van der Geest S; Lowe S; Verbon A; Koopmans PP; Van Crevel R; de Groot R; Keuter M; Post F; van der Ven AJ; Warris A; van der Ende ME; Gyssens IC; van der Feltz M; Nouwen JL; Rijnders BJ; de Vries TE; Driessen G; van der Flier M; Hartwig NG; Juttman JR; van Kasteren ME; Van de Heul C; Hoepelman IM; Schneider MM; Bonten MJ; Borleffs JC; Ellerbroek PM; Jaspers CA; Mudrikove T; Schurink CA; Gisolf EH; Geelen SP; Wolfs TF; Faber T; Tanis AA; Groeneveld PH; den Hollander JG; Duits AJ; Winkel K; Back NK; Bakker ME; Berkhout B; Jurriaans S; Zaaijer HL; Cuijpers T; Rietra PJ; Roozendaal KJ; Pauw W; van Zanten AP; Smits PH; von Blomberg BM; Savelkoul P; Pettersson A; Swanink CM; Franck PF; Lampe AS; Jansen CL; Hendriks R; Benne CA; Veenendaal D; Storm H; Weel J; van Zeijl JH; Kroes AC; Claas HC; Bruggeman CA; Goossens VJ; Galama JM; Melchers WJ; Poort YA; Doornum GJ; Niesters MG; Osterhaus AD; Schutten M; Buiting AG; Swaans CA; Boucher CA; Schuurman R; Boel E; Jansz AF; Veldkamp A; Beijnen JH; Huitema AD; Burger DM; Hugen PW; van Kan HJ; Losso M; Duran A; Vetter N; Karpov I; Vassilenko A; Mitsura VM; Suetnov O; Clumeck N; De Wit S; Poll B; Colebunders R; Kostov K; Begovac J; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Lundgren J; Benfield T; Kirk O; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Oestergaard L; Zilmer K; Ristola M; Girard PM; Vanhems P; Rockstroh J; Schmidt R; van Lunzen J; Degen O; Stellbrink HJ; Bogner J; Kosmidis J; Gargalianos P; Xylomenos G; Perdios J; Panos G; Filandras A; Karabatsaki E; Sambattakou H; Banhegyi D; Mulcahy F; Yust I; Turner D; Burke M; Pollack S; Hassoun G; Maayan S; Chiesi A; Mazeu I; Pristera R; Gabbuti A; Montesarchio E; Gargiulo M; Iacomi F; Vlassi C; Finazzi R; Galli M; Ridolfo A; Rozentale B; Aldins P; Chaplinskas S; Hemmer R; Staub T; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Prokopowicz D; Wiercinska-Drapalo A; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Antunes F; Valadas E; Mansinho K; Maltez F; Duiculescu D; Rakhmanova A; Vinogradova E; Buzunova S; Jevtovic D; Mokrás M; Staneková D; González-Lahoz J; Soriano V; Martin-Carbonero L; Labarga P; Clotet B; Jou A; Conejero J; Tural C; Gatell JM; Miró JM; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Karlsson A; Persson PO; Flamholc L; Boffi E; Kravchenko E; Chentsova N; Barton S; Johnson AM; Mercey D; Johnson MA; Murphy M; Weber J; Scullard G; Fisher M; Brettle R; Gatell J; Gazzard B; Friis-Møller N; Bannister W; Ellefson M; Borch A; Podlekareva D; Holkmann Olsen C; Kjaer J; Peters L; Reekie J; Raffanti S; Dieterch D; Becker S; Scarsella A; Fusco G; Most B; Balu R; Rana R; Beckerman R; Ising T; Fusco J; Irek R; Johnson B; Hirani A; DeJesus E; Pierone G; Lackey P; Irek C; Johnson A; Burdick J; Leon S; Arch J; Helm EB; Carlebach A; Müller A; Haberl A; Nisius G; Lennemann T; Stephan C; Bickel M; Mösch M; Gute P; Locher L; Lutz T; Klauke S; Knecht G; Khaykin P; Doerr HW; Stürmer M; Babacan E; von Hentig N; Beylot J; Dupon M; Longy-Boursier M; Pellegrin JL; Ragnaud JM; Salamon R; Thiébaut R; Lewden C; Lawson-Ayayi S; Dupon M; Mercié P; Moreau JF; Morlat P; Bernard N; Lacoste D; Malvy D; Neau D; Blaizeau MJ; Decoin M; Delveaux S; Hannapier C; Labarrère S; Lavignolle-Aurillac V; Uwamaliya-Nziyumvira B; Palmer G; Touchard D; Balestre E; Alioum A; Jacqmin-Gadda H; Bonarek M; Bonnet F; Coadou B; Gellie P; Nouts C; Bocquentin F; Dutronc H; Lafarie S; Aslan A; Pistonne T; Thibaut P; Vatan R; Chambon D; De La Taille C; Cazorla C; Ocho A; Viallard JF; Caubet O; Cipriano C; Lazaro E; Couzigou P; Castera L; Fleury H; Lafon ME; Masquelier B; Pellegrin I; Breilh D; Blanco P; Loste P; Caunègre L; Bonnal F; Farbos S; Ferrand M; Ceccaldi J; Tchamgoué S; De Witte S; Buy E; Alexander C; Barrios R; Braitstein P; Brumme Z; Chan K; Cote H; Gataric N; Geller J; Guillemi S; Harrigan PR; Harris M; Joy R; Levy A; Montaner J; Montessori V; Palepu A; Phillips E; Phillips P; Press N; Tyndall M; Wood E; Yip B; Bhagani S; Breen R; Byrne P; Carroll A; Cuthbertson Z; Dunleavy A; Geretti AM; Heelan B; Johnson M; Kinloch-de Loes S; Lipman M; Madge S; Marshall N; Nair D; Nebbia G; Prinz B; Shah S; Swader L; Tyrer M; Youle M; Chaloner C; Grabowska H; Holloway J; Puradiredja J; Ransom D; Tsintas R; Bansi L; Fox Z; Harris E; Hill T; Lampe F; Lodwick R; Smith C; Amoah E; Booth C; Clewley G; Garcia Diaz A; Gregory B; Janossy G; Labbett W; Thomas M; Read R; Krentz H; Beckthold B; Schmeisser N; Alquézar A; Esteve A; Podzamczer D; Murillas J; Romero A; Agustí C; Agüero F; Ferrer E; Riera M; Segura F; Navarro G; Force L; Vilaró J; Masabeu A; García I; Guadarrama M; Montoliu A; Ortega N; Lazzari E; Puchol E; Sanchez M; Blanco JL; Garcia-Alcaide F; Martinez E; Mallolas J; López-Dieguez M; García-Goez JF; Sirera G; Romeu J; Negredo E; Miranda C; Capitan MC; Olmo M; Barragan P; Saumoy M; Bolao F; Cabellos C; Peña C; Sala M; Cervantes M; Jose Amengual M; Navarro M; Penelo E; Barrufet P; Raper JL; Mugavero MJ; Willig JH; Schumacher J; Chang PW; Westfall AO; Cloud G; Lin HY; Acosta EP; Colette-Kempf M; Allison JJ; Pisu M
  •  go-up   go-down


11. Novelli G, Rossi M, Ferretti G, Nudo F, Bussotti A, Mennini G, Novelli L, Ferretti S, Antonellis F, Martelli S, Berloco PB: Molecular adsorbent recirculating system treatment for acute hepatic failure in patients with hepatitis B undergoing chemotherapy for non-Hodgkin's lymphoma. Transplant Proc; 2005 Jul-Aug;37(6):2560-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular adsorbent recirculating system treatment for acute hepatic failure in patients with hepatitis B undergoing chemotherapy for non-Hodgkin's lymphoma.
  • Despite the use of these antiviral agents at the time of clinical hepatitis, some HBsAg-positive patients still develop hepatic failure and die.
  • We used the Molecular Adsorbent Recirculating System (MARS) (MARS Monitor; Teraklin AG, Rostock, Germany) to treat 5 HBsAg-positive lymphoma patients with acute hepatic failure due to chemotherapy despite lamivudine treatment.
  • Before and after each treatment we monitored the parameters of neurological status (EEG, cerebral CT and Glasgow coma score), hemodynamic parameters, acid-base equilibrium and blood gases as well as hepatic and renal function.
  • The 2 patients died because MARS treatment was started too late, with Glascow coma score grade IV, hemodynamic instability, and mechanical ventilator assistance.
  • [MeSH-major] Hepatitis B / complications. Liver Failure, Acute / therapy. Lymphoma, Non-Hodgkin / complications. Sorption Detoxification / methods

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182743.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B e Antigens
  •  go-up   go-down


12. Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C: [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Orv Hetil; 2009 Oct 18;150(42):1937-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary central nervous system lymphoma is defined as an extranodal lymphoma arising in the central nervous system in the absence of systemic disease.
  • AIMS: In this retrospective survey we analyzed the result of combined treatment (systemic and intrathecal chemotherapy followed by consolidation radiotherapy) in patients with primary or relapsed central nervous system lymphomas diagnosed and treated in our hematological department between 1998-2009.
  • PATIENTS AND METHODS: During this period (mean follow-up of 13.2 months) from 427 patients with newly diagnosed non-Hodgkin's lymphomas, 22 primary central nervous system lymphoma was diagnosed (5.15%, 16 cerebral and 6 spinal cord lymphoma cases).
  • All central nervous system lymphoma specimens taken with neurosurgical resection or stereotaxic biopsies were confirmed histopathologically.
  • All cerebral lymphoma cases proved to be diffuse large B-cell of origin, while in epidural lymphomas low grade subtypes also occurred.
  • In cerebral lymphoma (every patients had supratentorial localization) the following combined therapy protocol was used: up to three courses of high dose methotrexate (HD MTX 3g/m 2 in a single dose for 4 hours lasting drop-infusion) were given at 4-week intervals, followed by leucovorin-rescue 24 hours after MTX infusion.
  • RESULTS: Complete remission has been achieved in 9 patients with cerebral and in 4 patients with spinal cord lymphoma (13/22; 59.0%), however, one relapsed patient became resistant and later expired, despite salvage therapy.
  • Mean of the overall survival (OS) in cerebral lymphoma was 19.5 (3-46, median of 10) months, in epidural group 14.1 (2-76, median of 5) months, whilst mean time to progression (TTP) was 4.5 (2-6.5, median of 4 months).
  • CONCLUSION: In primary central nervous system lymphoma, basic treatment HD methotrexate together with intrathecal combination of methotrexate + cytosin-arabinosid + dexamethasone followed by whole-brain irradiation of at least 30 Gy could produce a medium response rate in our study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Epidural Space. Female. Humans. Hungary / epidemiology. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Positron-Emission Tomography. Prednisone / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Salvage Therapy / methods. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812012.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down






Advertisement